# Boston Scientific Corporation (BSX)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/BSX/primer

## Business Model

---
ticker: BSX
step: 01
generated: 2026-05-12
source: quick-research
---

### Boston Scientific Corporation (BSX) — Business Overview

#### Business Description
Boston Scientific is the world's fastest-growing major medical device company, with FY2025 revenue of $20.1B (+19.9%) — by far the highest organic growth rate among large-cap medtech (vs. Medtronic mid-single-digit, J&J MedTech mid-single-digit, Stryker high-single-digit). Growth is led by the **electrophysiology franchise** anchored by **FARAPULSE Pulsed Field Ablation (PFA)** — the fastest-adopted cardiovascular device of the past decade — and **Watchman left atrial appendage closure**. BSX has positioned itself as the leader in two of medtech's fastest-growing categories: atrial fibrillation ablation and stroke prevention from afib.

#### Revenue Model
Two reportable segments:
- **MedSurg** (~$10B, growing ~+10%) — Endoscopy + urology + neuromodulation:
  - **Endoscopy** (~$3.5B+) — GI endoscopy, pulmonary, advanced bronchoscopy.
  - **Urology** (~$2.5B) — Stone management, urology services, peripheral.
  - **Neuromodulation** (~$1B) — Pain management, deep brain stimulation, spinal cord stim.
- **Cardiovascular** (~$10B+, growing ~+23%) — Three sub-franchises:
  - **Cardiology** (~$5B+) — Includes Watchman ($2B+ run-rate; +28% YoY).
  - **Electrophysiology** (~$3.4B annualized) — FARAPULSE PFA, mapping catheters, ablation.
  - **Peripheral Interventions** + structural heart + coronary stents.

Revenue mix is overwhelmingly recurring (consumables, single-use devices, capital-attached); EP segment is the highest-growth driver and the most concentrated competitive focus.

#### Products & Services
- **FARAPULSE PFA**: Pulsed field ablation system for atrial fibrillation; FDA-approved 2024; ~$1B+ revenue in first 12 months (fastest cardiovascular device launch in a decade). Expanded label for persistent AF (July 2025).
- **Faraflex PFA + Farapoint PFA**: Next-generation PFA catheters with improved workflow + mapping integration.
- **Watchman FLX**: Left atrial appendage closure device for AF stroke prevention; +28.4% growth FY25; $2B+ franchise.
- **Endoscopy**: GI navigators, hemostasis, dilation, biopsy, advanced bronchoscopy.
- **Urology**: Kidney stone management (LithoVue), prostate hyperplasia, men's health.
- **Neuromodulation**: WaveWriter SCS (spinal cord stim), Vercise DBS, Precision spinal cord stim.
- **Peripheral Interventions**: PAD treatment, drug-coated balloons, atherectomy, stents.
- **Coronary**: Drug-eluting stents (Synergy XD), balloon angioplasty.
- **Cardiac Rhythm Management**: Pacemakers, defibrillators (smaller share vs. MDT/ABT).
- **Structural Heart**: Acurate transcatheter aortic valve (TAVR — late entrant), Eluvia stent.

#### Customer Base & Go-to-Market
- **Hospitals + cardiac centers**: Electrophysiology labs (~5,000+ globally), interventional cardiology, structural heart programs.
- **Ambulatory Surgery Centers (ASCs)**: Endoscopy + urology procedures increasingly moving to ASCs.
- **GI specialists**: ~16,000+ US gastroenterologists for endoscopy products.
- **Pain management physicians**: Neuromodulation customer base.

Geographic mix: ~60% US, ~40% international. Significant growth in Asia-Pacific + Europe for EP.

#### Competitive Position
BSX has emerged as the **clear leader in electrophysiology PFA**, having significantly outpaced Medtronic's PulseSelect, Johnson & Johnson Biosense Webster Varipulse, and Abbott (small EP presence). Structural advantages:

1. **FARAPULSE first-mover PFA + best clinical data** — AVANT GUARD trial showed statistical superiority over antiarrhythmic drugs; market preference firmly with Farapulse.
2. **Watchman franchise compounding at 28%+** — AF treatment + stroke prevention bundle creates cross-sell with EP.
3. **Bolt Medical acquisition** — Intravascular lithotripsy (IVL) entry; competes with Shockwave (now Johnson & Johnson MedTech).
4. **SoniVie acquisition** — Renal denervation hypertension treatment platform.
5. **R&D + clinical trial leadership** — Multiple Phase 3 + pivotal trials simultaneously running across EP + structural heart + endoscopy.

**Competitive challenges:**
- **Medtronic** — Major Cardiac Rhythm Management franchise + Affera EP acquisition (still smaller scale).
- **Johnson & Johnson MedTech (Biosense Webster + Shockwave)** — Direct EP + IVL competition.
- **Abbott** — Newer Volt PFA entry; smaller but well-funded.
- **PFA category competition increasing** — Affera (Medtronic), Varipulse (J&J), PulseSelect (MDT). Market share at 35–38% currently but defensible with Faraflex / Farapoint.

#### Key Facts
- Founded: 1979
- Headquarters: Marlborough, Massachusetts
- Employees: ~50,000
- Exchange: NYSE
- Sector / Industry: Health Care / Medical Devices
- Market Cap: ~$165B
- FY2025 Revenue: $20.074B (+19.9% reported)
- FY2025 Organic Growth: ~+15%
- FARAPULSE Revenue (Year 1): >$1B
- Watchman Franchise Annual Run-rate: ~$2B+
- Major Recent Acquisitions: Bolt Medical (IVL), SoniVie (renal denervation), Axonics (~$3.7B, sacral neuromodulation 2024)
- Dividend: None (growth focus)
- Q4 2025 Cardiovascular Growth: +23.2%

## Financial Snapshot

---
ticker: BSX
step: 04
generated: 2026-05-12
source: quick-research
---

### Boston Scientific Corporation (BSX) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY (FY25) |
|--------|--------|--------|--------|------------|
| Net Sales | $14.2B | $16.75B | $20.07B | +19.9% reported / +15.8% organic |
| Adjusted Operating Margin | 25.6% | 26.7% | 27.5% | +80 bps |
| Adjusted EPS | $2.05 | $2.51 | $3.10 | +24% |

#### Segment Detail (FY2025)

| Segment | FY25 Revenue | YoY |
|---------|--------------|-----|
| Cardiovascular | $13.3B | +23.2% |
| - Electrophysiology (FARAPULSE) | ~$3.4B annualized | +37% (Q4); >$1B in FARAPULSE Year 1 |
| - Watchman | ~$2.0B | +28% |
| - Cardiology + Peripheral + Coronary | ~$7B+ | mid-teens |
| MedSurg | ~$6.8B | +10% |
| - Endoscopy | ~$3.5B | +mid-single-digit |
| - Urology | ~$2.5B | high-single-digit |
| - Neuromodulation | ~$1B | mid-single-digit |

#### FY2026 Guidance (Revised April 2026 post Q1)

| Metric | 2026 Guide |
|--------|-----------|
| Reported Sales Growth | +10.5–11.5% (initial Feb) → adjusted post-Q1 |
| Organic Sales Growth | +6.5–8.0% (revised down from 10–11%) |
| Adjusted Operating Margin Expansion | +50–75 bps |
| Adjusted EPS | $3.34–3.41 (+9–11%, revised down from $3.43–3.49) |
| Free Cash Flow | ~$4B (revised down from $4.2B) |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$4.5B |
| Free Cash Flow | ~$3.7B |
| Capital Expenditures | ~$0.8B |
| Cash & Marketable Securities | ~$2B |
| Total Debt | ~$9B |
| Net Debt | ~$7B |
| Net Debt / EBITDA | ~1.3x |
| Dividend | None |

#### Key Ratios (approximate)
- P/E: ~34x (FY26 adjusted EPS midpoint) | EV/EBITDA: ~25x | FCF Yield: ~2.4%
- Revenue Growth (FY25): +19.9% reported, +15.8% organic
- Adjusted Operating Margin: 27.5%
- Net Debt / EBITDA: ~1.3x
- No dividend; growth-stock profile

#### Growth Profile
FY25 was a banner year — fastest growth in the major medtech peer group:
- Reported revenue +19.9%; organic +15.8%
- Electrophysiology (FARAPULSE) $3.4B annualized run-rate, fastest cardiovascular device launch in a decade
- Watchman LAAC franchise +28% YoY
- Adjusted operating margin expanded 80 bps to 27.5%
- Adjusted EPS +24%

FY26 guidance was revised down in April 2026 (Q1 earnings) from initial February guide:
- Organic growth: 10–11% → 6.5–8.0%
- Adjusted EPS: $3.43–3.49 → $3.34–3.41

The downward revision triggered a -18% stock reaction in Q1 2026. Concerns: PFA market share competition from Medtronic Affera + J&J Varipulse; PulseSelect FDA expansion; EP segment growth deceleration from 37% (Q4 25) to expected mid-teens FY26.

#### Forward Estimates
FY2026 Guide (revised April 2026):
- Net Sales: ~$22B (+10–11%)
- Organic Growth: +6.5–8.0%
- Adjusted EPS: $3.34–3.41
- FCF: ~$4B

Bull case: FARAPULSE share defends 38%+ against Medtronic Affera + J&J Varipulse; Bolt Medical IVL adds incremental growth; international EP expansion accelerates; multiple recovers to 38–40x P/E. Bear case: FARAPULSE share erosion to 25–30% over 2026–27; PFA category commoditizes; revenue growth decelerates to single-digit FY27; multiple compresses to 25x P/E. Consensus targets $130–145 vs. trading ~$105–115 (~20–35% implied upside post Q1 sell-off).

## Recent Catalysts

---
ticker: BSX
step: 12
generated: 2026-05-12
source: quick-research
---

### Boston Scientific Corporation (BSX) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **FARAPULSE — fastest cardiovascular launch in a decade** — >$1B revenue in Year 1; expanded label for persistent AF (July 2025); AVANT GUARD trial showed statistical superiority over antiarrhythmic drugs. Multi-billion peak potential in $10B+ atrial fibrillation ablation market.
2. **Watchman LAAC franchise +28% growth at $2B+ run-rate** — Left atrial appendage closure for AF stroke prevention; multi-decade tailwind from rising AF prevalence + aging population + concomitant cross-sell with EP.
3. **Next-gen PFA platform (Faraflex + Farapoint)** — Workflow improvements increased PVI durability from 80.4% to 96.4%; defends share against competitor PFA entries.
4. **Adjusted operating margin expanded 80 bps to 27.5%** — Mix-shift toward higher-margin EP + Watchman drives operating leverage; FY26 guide +50–75 bps further expansion.
5. **Cross-sell EP + Watchman = afib care ecosystem** — BSX is the only major medtech with both PFA ablation + LAAC closure in the same portfolio; integrated AF care platform.
6. **Bolt Medical IVL acquisition** — Intravascular lithotripsy entry post-J&J's Shockwave acquisition opens new $1B+ peripheral interventions market.
7. **SoniVie renal denervation** — Uncontrolled hypertension platform; potential blockbuster in 2027–28.
8. **Buying opportunity post-Q1 2026 sell-off (-18%)** — Adjusted EPS guide cut prompted overreaction; FY26 still implies +9–11% EPS growth at >27% operating margin.

#### Bear Case Risks

1. **FARAPULSE share erosion concerns** — Q1 2026 guidance cut triggered fears that Medtronic Affera + J&J Varipulse + PulseSelect are gaining share faster than expected. Market analysts forecasting BSX PFA share at 35–38% (down from 50%+ at FARAPULSE launch).
2. **PFA category commoditization** — Multiple major players (MDT, J&J, ABT) with PFA platforms; pricing pressure + share fragmentation could compress margins long-term.
3. **Premium valuation (~34x FY26 P/E) with growth deceleration** — Organic growth guide cut from 10–11% to 6.5–8.0% creates multiple-compression risk. Stock already corrected -18% in Q1 2026 but valuation remains elevated vs. peers.
4. **Acurate TAVR — late entry into mature market** — Acurate Neo + Acurate Prime competing against Edwards Sapien 3 + Medtronic Evolut; uphill battle for share.
5. **Coronary stents legacy decline** — Synergy XD growth has plateaued; reduced importance to overall mix.
6. **No dividend; capital return entirely via M&A reinvestment** — Limits income investor appeal; relies on growth execution.
7. **Q4 2025 guidance miss / 2026 guide revision** — Operational execution concerns post the Q1 2026 EPS guide cut.
8. **EP capital equipment / lab capacity constraints** — Continued FARAPULSE rollout depends on cath labs adding PFA capability; potential capacity ceiling.

#### Upcoming Events
- **Q2 2026 earnings (late July 2026)**: Mid-year guide check + EP growth trajectory.
- **Q3 2026 earnings (late October 2026)**: Final guide check before FY27 setup.
- **Bolt Medical / SoniVie integration milestones**: Revenue contribution disclosures.
- **Heart Rhythm 2026 / Heart Rhythm 2027 conferences**: Major PFA clinical data readouts.
- **Acurate TAVR commercial launches**: Quarterly procedure volume disclosures.
- **Medtronic Affera + J&J Varipulse FDA / commercial launches**: Competitive monitoring.
- **Annual Investor Day**: Multi-year financial framework updates.

#### Analyst Sentiment
Consensus rating is **Buy / Overweight** (~75% Buy, 23% Hold, 2% Sell). Price targets cluster $130–145 vs. trading ~$105–115 (~20–35% implied upside post-Q1 sell-off). Bull case targets ~$165 on continued PFA dominance + Bolt integration; bear case ~$90 on PFA share loss + multiple compression. Morgan Stanley, Goldman, Wedbush, JPM, BMO maintain Buy/Overweight; Wells Fargo at Equal-Weight; Bernstein at Outperform.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/bsx
- Full research API: GET /api/v1/research/BSX/memo
- Coverage universe: /stocks